ACM
PSTX

Antonetti Capital Management’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Antonetti Capital Management’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$952 Buy
400
+300
+300% +$629 ﹤0.01% 291
2023
Q2 		$176 Hold
100
– – ﹤0.01% 329
2023
Q1 		$308 Hold
100
– – ﹤0.01% 329
2022
Q4 		$530 Buy
+100
New +$457 ﹤0.01% 322

Other funds holding PSTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Antonetti Capital Management's PSTX Position: Q3 2023 in Review

Antonetti Capital Management increased its Poseida Therapeutics, Inc. Common Stock (PSTX) stake by 300% in Q3 2023, buying an estimated $629 and bringing the position to 400 shares worth $952. The position accounts for ﹤0.01% of the portfolio, ranked #291.

Antonetti Capital Management first reported a position in PSTX in Q4 2022 and has held it in 4 quarters since. 86 funds tracked by Wall St. Rank hold PSTX as of Q3 2023.

  • Antonetti Capital Management held 400 shares of Poseida Therapeutics, Inc. Common Stock worth $952 as of Q3 2023.
  • Antonetti Capital Management bought 300 Poseida Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $629.
  • Poseida Therapeutics, Inc. Common Stock made up ﹤0.01% of Antonetti Capital Management's portfolio in Q3 2023, its #291 holding.
  • Antonetti Capital Management first reported a position in Poseida Therapeutics, Inc. Common Stock in Q4 2022 and has held it in 4 quarters since.
  • 86 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Antonetti Capital Management's 13F filing for Q3 2023, filed 9 Nov 2023.